Navigation Links
Tufts researcher elected 2010 AAAS Fellow for work in superbugs and heat-stable vaccines
Date:1/14/2011

BOSTON (January 14, 2011) Abraham L. (Linc) Sonenshein, PhD, professor of molecular biology and microbiology at Tufts University School of Medicine and member of the genetics and molecular microbiology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts has been awarded the distinction of AAAS Fellow.

Election as a Fellow is an honor bestowed upon AAAS members by their peers. Fellows are awarded because of their scientifically or socially distinguished efforts to advance science or its applications. Sonenshein was elected for his distinguished contributions to the understanding of gene regulation, sporulation and pathogenesis in Gram-positive bacteria.

Sonenshein, who is also the acting chair of molecular biology and microbiology at Tufts School of Medicine, studies the regulation of gene transcription in the spore-forming bacteria Bacillus subtilis and Clostridium difficile, and the relationship of sporulation to pathogenesis.

His work with the "superbug," C. difficile which causes severe diarrhea in patients and sometimes death, showed that the bacteria only produce toxins when they are limited for nutrients. Essentially, protein that monitors the nutrient levels inside C. difficile cells prevents toxin production when the bacteria have enough to eat.

This and his other work with C. difficile are important steps toward the development of a drug that may prevent hospital patients from falling ill.

In ongoing work, he is collaborating with scientists at the Cummings School of Veterinary Medicine at Tufts and Boston University to use the harmless B. subtilis bacterium as the basis for low-cost, needle-free and heat-stable vaccines. In a study published in the November 2010 issue of Clinical and Vaccine Immunology, one such vaccine using nasal drops instead of needles effectively induced an immune response in mice and protected them from rotavirus infection. Rotavirus is a common cause of severe diarrheal disease that is responsible for approximately 500,000 deaths among children in the developing world every year.

The new vaccine delivery system has also been tested successfully against tetanus. A study published in Vaccine in September 2010 established that the tetanus vaccine is effective even after being stored for more than a year at 113F. The new vaccine delivery system is currently being tested with diphtheria and pertussis.


'/>"/>

Contact: Siobhan E. Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. Tufts Medical Center and Boston Medical Center Nurses Hold a Joint Informational Picket to Protest Unsafe Staffing and Practice Conditions
2. Impressive lineup of speakers at Tufts nutrition conference
3. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
4. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
5. Researchers discover new way to kill pediatric brain tumors
6. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
7. Tiny fruit fly could offer big clues in fight against obesity, researcher says
8. Researchers create drug to keep tumor growth switched off
9. MSU researcher linking breast cancer patients with alternative therapies
10. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
11. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre (SCHC), ... Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a ... the Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among ... all types and genders. And the need for advanced services is growing. , ... top-rated cancer care program, in collaboration with their non-profit partners in their fight against ...
(Date:2/26/2017)... Ireland (PRWEB) , ... February 26, 2017 , ... ... as in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 ... 1 (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... patients after receiving cognitive rehabilitation, according to a study released today at the ... that cognitive rehabilitation programs are proven to be effective in improving cognitive function ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology: